NCT00659178View on ClinicalTrials.gov

Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 18, 2008

Primary Completion Date

February 18, 2011

Study Completion Date

February 18, 2011

Conditions
Neoplasms, Ovarian
Interventions
DRUG

SB-485232 (interleukin 18), pegylated liposomal doxorubicin

SB-485232 (interleukin 18), pegylated liposomal doxorubicin

Trial Locations (3)

19104

GSK Investigational Site, Philadelphia

33136

GSK Investigational Site, Miami

94305-5317

GSK Investigational Site, Stanford

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00659178 - Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter